Wave Life Sciences (WVE) Director Heidi Wagner Exercises Options, Sells Shares

What Happened
Heidi L. Wagner, a director of Wave Life Sciences (WVE), exercised 7,000 vested stock options at $5.97 per share (total cost $41,790) on August 11, 2026 and immediately sold 7,000 common shares in the open market at $6.01 per share (gross proceeds $42,070). The filings show the option conversion (derivative disposition) associated with the exercise. The transactions were carried out under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: August 11, 2026; Form 4 filed August 13, 2026 (period of report 2026-08-11).
• Exercise: 7,000 options exercised at $5.97 — cash paid $41,790.
• Sale: 7,000 shares sold open market at $6.01 — gross proceeds $42,070.
• Derivative entry: 7,000 derivative units reported disposed at $0 (represents conversion/settlement of the options into shares).
• Footnotes: Transactions were executed pursuant to a Rule 10b5-1 trading plan adopted March 6, 2026; the options were fully vested.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: no late-filing flag indicated in the provided information.

Context
This was an option exercise followed by an immediate sale (commonly a cashless exercise/sale under a trading plan), which is often routine for insiders exercising vested options to cover exercise costs or diversify. The company redomiciled from Singapore to Delaware on August 7, 2026 (a technical corporate change that did not alter shareholder percentages) — noted in the filing remarks.